Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.

CURRENTLY ENROLLING STUDIES

HOLLYWOOD NEUROLOGY

For more information, please call: 954-366-0277.

Merck – APECS:   Memory Loss
A two-year study with a new oral drug as a potential disease-modifying therapy in patients 50 to 85 years old who have been experiencing memory loss for a year.

Merck – EPOCH:   Alzheimer’s Disease
A two-year study to evaluate potential disease-modifying therapy (the same medicine as in APECS) in patients 55 to 85 years old with mild to moderate Alzheimer’s Disease.

Merck – 012:   Alzheimer’s Disease
A 6-month study evaluating the effectiveness of a new oral medicine for those patients between 55 and 85 years old and already on a stable dose of Aricept for treating the symptoms of mild to moderate Alzheimer’s Disease.

Roche – MARGUERITE ROAD:   Alzheimer’s Disease
A two-year study with a potential disease modifying treatment given by subcutaneous injection in patients 50 to 90 years old with mild Alzheimer’s Disease.

Toyoma / Alzheimer’s Disease Cooperative Study (UCSD) – NOBLE:
A one-year study to evaluate the neuro-protective effects of a new oral medication in patients who are 55 to 85 years old with mild to moderate Alzheimer’s Disease and on Aricept for at least 6 months with a stable dose for at least 3 months.

Eli Lilly – EXPEDITION 3:   Alzheimer’s Disease
A two-year study to evaluate a potential disease modifying treatment given monthly by intravenous infusion on the effect of passive immunization on the progression of mild Alzheimer’s Disease in patients who are 55 to 90 years old.

Allergan – 127:   Post-Stroke Upper Limb Spasticity
 Botox® Treatment in Adult Patients with Upper Limb Spasticity – A 16-week study evaluating Botox in patients 18 to 80 years old with upper limb spasticity involving the elbow and shoulder due to stroke.

Guerbet – REMIND:   Brain Tumors
A 6-week study evaluating adult patients with known or highly suspected brain tumors that have been detected by previous CT or MRI examination and who are scheduled to undergo a routine contrast-enhanced MRI.  The contrast agent in this study is already FDA approved!

HOLLYWOOD PULMONARY

Lead Study Coordinator: Lucy Vargas
954-981-4491 / lvargas@infinityclinicalresearch.com

Forest – ASCENT COPD:   Moderate to Severe COPD with High Cardiovascular Risk
A three-year post-marketing study to evaluate the effect of aclidinium bromide (Tudorza Pressair) on long-term cardiovascular safety and COPD attacks in patients 40 years old or older who are current or former smokers, with moderate to very severe COPD and a history of cardiovascular or cerebrovascular disease and/or significant cardiovascular risk.  This medicine is already FDA approved!

Glaxo SmithKline – IMPACT:   Chronic Obstructive Pulmonary Disease
A one-year study comparing the efficacy, safety and tolerability of  the investigational fixed dose triple combination therapy fluticasone furoate / umeclidinium / vilanterol trifentate (FF / UMEC / VI) compared with one of the FDA approved fixed dose dual combinations of Breo Ellipta (fluticasone furoate / vilanternol), a medicine similar to Advair, and Anoro Ellipta (umeclidinium / vilanterol) a medicine similar to Spiriva plus a fast-acting broncho-dilator; all administered once-daily in the morning with a dry powder inhaler in patients 40 years old or older with chronic obstructive pulmonary disease who are current or former smokers of at least 10 years.

HOLLYWOOD CARDIOLOGY

Study Coordinator: Becky Nembhard
954-965-4900 x173 / rnembhard@infinityclinicalresearch.com

Eisai – TIMI-61 – CAMELLIA:  Cardiovascular Outcomes Trial 
A five-year study to evaluate the effect of long-term treatment with BELVIQ (lorcaserin HCI) on the incidence of major adverse cardiovascular events and conversion to type 2 diabetes in patients with cardiovascular disease or multiple cardiovascular risk factors.

Boehringer Ingelheim – CARMELINA: Cardiovascular Risk and Renal Outcomes in Type II Diabetics
A four-year post-marketing cardiovascular safety and renal outcomes study with an FDA approved medicine Tradjenta (lingaliptin), in patients who are 18 years old, have type 2 diabetes on a stable dose of antidiabetic medicine, and are at high risk for cardiovascular events.

Sanofi – ODYSSEY: Recent Acute Coronary Syndrome with Obstructive Coronary Disease
A five-year study comparing a novel new class of drug on the occurrence of cardiovascular events in patients at least 40 years old who have experienced an acute coronary syndrome (ACS) event (unstable angina or heart attack) and despite intensive lipid modifying or statin therapy, are not adequately controlled.

POMPANO BEACH NEUROLOGY

Lead Study Coordinator: Irys Caristo
954-738-1686 / icaristo@infinityclinicalresearch.com

Novartis – ASSESS:  Relapsing-Remitting MS
A one-year study to compare efficacy and safety of 2 doses or oral Fingolimod (Gilenya) to Copaxone in adults at least 18 years old with relapsing-remitting multiple sclerosis.

Novartis – EXPAND:  Secondary Progressive MS
A four-year study evaluating a new oral medicine in patients 18 to 60 years old with secondary progressive multiple sclerosis.

Receptos – RADIANCE:  Relapsing MS
A two-year study to evaluate the  efficacy and safety of a new oral medication compared to Avonex in adults at least 18 years old with relapsing forms of multiple sclerosis.

Sun Pharma – SPASTICITY:  Spasticity Due to MS
A 22-week study evaluating a new formulation of extended release baclofen in patients 18 years and older with spasticity due to multiple sclerosis.

Sun Pharma – SPASTICITY OL:  Spasticity Due to MS
A long-term safety study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to MS, who completed 26 weeks of treatment in the spasticity trial.

m4s0n501